From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q4 2021 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“已获批准、指定、列入、合格、注册、报销或预先授权”的买家内部采购、报销、处方集、规格、采购、网络、目录或计划系统,从而使得公司未来业务的重要部分可以在没有每笔订单单独销售事件的情况下到达,并且管理层是否传达了这种准入状态是新的,以至于它解锁的大部分量仍在前方。 在记录中,管理层讨论了成为“美国第一家数字市场银行”,利用银行能力,增加净利息收入,保留贷款,投资于营销、产品体验和基础设施。他们提到“我们的市场银行已经满足了这些需求,我们正在构建下一代能力”。但具体关于“被列入买家系统”或“默认路径”的表述?管理层没有明确提到被列入任何供应商名单、处方集、网络等。他们谈论的是商业模式转变(成为银行),而不是被纳入买家的采购系统。他们提到“我们预计2022年将交付另一个创纪录的年份”,但这是关于增长,不是关于准入状态。 管理层提到“我们相信我们的核心能力和战略优势将使我们能够成功应对环境因素”,但未提及具体准入。他们谈论“我们的市场银行模式”,但这是关于他们自己的平台,不是被纳入外部系统。 因此,没有证据表明管理层描述了公司最近被纳入买家系统。答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.